VivoSim Labs, INC. (VIVS) stock
VIVSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$0.12−0.00 (-0.08%)
Close on Nov 18, 2026Market cap $383.32KP/E –Yield –
VivoSim Labs revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
VivoSim Labs's revenue for the twelve months ending Jun 30, 2026 was $112.00K, down 21.1% year over year. For fiscal 2026 it was $131.00K, down 9.0% from the year before. Over ten years it grew -21.5% a year on average. The highest annual figure on record is $4.60M in fiscal 2018.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $131.00K | -9.0% |
| FY2025 | Mar 31, 2025 | $144.00K | +32.1% |
| FY2024 | Mar 31, 2024 | $109.00K | -70.5% |
| FY2023 | Mar 31, 2023 | $370.00K | -75.3% |
| FY2022 | Mar 31, 2022 | $1.50M | – |
| FY2021 | Mar 31, 2021 | $0 | -100.0% |
| FY2020 | Mar 31, 2020 | $2.20M | -29.0% |
| FY2019 | Mar 31, 2019 | $3.09M | -32.8% |
| FY2018 | Mar 31, 2018 | $4.60M | +8.8% |
| FY2017 | Mar 31, 2017 | $4.23M | +185.2% |
| FY2016 | Mar 31, 2016 | $1.48M | +159.7% |
| FY2015 | Mar 31, 2015 | $571.00K | -52.3% |
| FY2012 | Dec 31, 2012 | $1.20M | +23.5% |
| FY2011 | Dec 31, 2011 | $969.00K | +60.7% |
| FY2010 | Dec 31, 2010 | $603.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $18.00K | -51.4% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $40.00K | -21.6% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $26.00K | +8.3% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $28.00K | -6.7% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $37.00K | -5.1% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $51.00K | +75.9% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $24.00K | +380.0% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $30.00K | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $39.00K | -48.0% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $29.00K | -82.1% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $5.00K | -96.2% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $0 | -100.0% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $75.00K | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $162.00K | -89.2% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $131.00K | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $77.00K | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $0 | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $1.50M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $0 | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $0 | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $0 | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $0 | -100.0% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $0 | -100.0% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $0 | -100.0% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $0 | -100.0% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $298.00K | -61.7% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $1.23M | +30.4% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $668.00K | -3.0% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $680.00K | -38.5% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $779.00K | -32.4% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $943.00K | -30.4% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $689.00K | -30.4% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $1.11M | +36.1% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $1.15M | +0.2% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $1.36M | -1.5% |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $990.00K | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $812.00K | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $1.15M | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | $1.38M | – |
See a number that looks wrong?